Pharmaceutical companies are placing their faith in the short-term and long-term gains that involvement in disease management promises.
Pharmaceutical companies are placing their faith in the short-term and long-term gains that involvement in disease management promises, according to New York-based market analysis firm Datamonitor.
More than 65% of top executives at leading companies surveyed by Datamonitor indicated they would double the size of their disease management efforts over the course of the next five years, the firm stated in its recent report titled "Disease Management: Is it working?" All executive-level survey respondents added that supporting a new product with a disease management program gave them a more competitive advantage when they sat down at negotiating tables with managed care formulary committees.
Eight out of 10 of those executives said they were concerned primarily with the short-term benefits of investing in disease management programs, primarily because they need to be able to demonstrate returns on investment to executive board members. Short-term advantages, according to Datamonitor, include:
• Being included on a managed care formulary.
• Reducing the discount - with which the pharmaceutical company has to agree - for inclusion on a formulary.
• Blocking a competitor's drug from inclusion on the same formulary.
• Increasing product sales by changing the way that drugs are prescribed and dispensed on a plan.
However, disease management appears to offer significant long-term gains as well. In addition to enhancing relations with managed care organizations, disease management programs can improve company, brand and disease awareness; increase identified prevalent populations through screening programs; and provide access to utilization data for use in product targeting, according to Datamonitor.
Although the disease management market is roughly valued between $300 million to $500 million, Datamonitor estimated that pharmaceutical companies' investment in the market is closer to $100 million, leaving the market with plenty of room to grow. PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.